Communiqués Basilea Pharmaceutica AG

Actions

BSLN

CH0011432447

Recherche biotechnologique et médicale

Temps réel estimé Cboe Europe 11:01:15 05/10/2026			Varia. 5j.	Varia. 1 janv.
66,50 ^CHF	-0,45 %		-2,78 %	+21,39 %

14/09	Repli des actions japonaises face aux appels à ralentir le développement de l'IA ; le pétrole progresse	MT
14/09	Une filiale d'Asahi Kasei lance une étude de phase II sur l'antifongique Cresemba pour les patients pédiatriques au Japon	MT

Communiqués

14/09	Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients	GL
18/08	Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track	GL
05/08	Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam	GL
29/07	Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix	GL
28/05	Basilea Pharmaceutica : Presentation (20260528 Basilea InvestorBooklet Final)	PU
28/05	Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam	GL
23/04	Basilea Pharmaceutica : Minutes (EN) (Basilea AGM 2026 Minutes English)	PU
15/04	Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting	GL
15/04	Basilea Pharmaceutica : AGM2026 Shareholder letter EN	PU
09/04	Basilea Pharmaceutica : Updated April 9, 2026	PU
09/04	Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420	GL
01/04	Basilea Pharmaceutica : Updated April 1, 2026	PU
23/03	Basilea Pharmaceutica : Updated March 23, 2026	PU
23/03	Basilea announces start of first‑in‑human study of novel antibiotic BAL2420	GL
26/02	Basilea Pharmaceutica : Updated February 25, 2026	PU
25/02	Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam	GL
17/02	Basilea Pharmaceutica : ESG report 2025	PU
17/02	Basilea Pharmaceutica : Updated February 17, 2026	PU
17/02	Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance	GL
09/02	Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	GL
13/01	Basilea joins INCATE to support antifungal innovation	GL
08/01	Basilea Pharmaceutica : Updated January 8, 2026	PU
08/01	Basilea provides portfolio update and outlook	GL
07/01	Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections	GL
11/12	Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic	GL